Trials / Completed
CompletedNCT02074982
Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
A 52-week, Multicenter, Randomized, Double-blind Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Ustekinumab and to Assess Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 676 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AIN457 300 mg | |
| DRUG | ustekinumab 45/90 mg | |
| DRUG | placebo secukinumab | Placebo |
Timeline
- Start date
- 2014-02-26
- Primary completion
- 2016-06-29
- Completion
- 2016-06-29
- First posted
- 2014-03-03
- Last updated
- 2017-07-21
- Results posted
- 2017-07-21
Locations
137 sites across 24 countries: United States, Australia, Austria, Belgium, Bulgaria, Canada, Denmark, Estonia, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, Norway, Portugal, Slovakia, South Korea, Spain, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02074982. Inclusion in this directory is not an endorsement.